News for hackers. Stuff that matters.

A comment on Goldman Sachs questions whether curing patients is a sustainable business model. Parent comment

Re:Goldman Sachs questions whether curing patients is a sust... by themaninthedark on Friday April 13, 2018 @11:21AM (#16830798)
"unnecessary duplication of safety trials because the FDA doesn't recognise any foreign medical safety standards, not even e.g. the EU)"

I would say in some cases that is a good thing. https://en.wikipedia.org/wiki/Thalidomide

[ Parent | on HN ]
Re:Goldman Sachs questions whether curing patients is a sust... by lmm on Saturday April 14, 2018 @03:17AM (#16836296)
It's very hard to argue against a safety trial - of course if you duplicate safety trials then there will be occasional cases where you catch something that the original trial missed. But ultimately far more people have died or suffered because a medicine wasn't available yet than been killed or hurt by medicine being approved too early.
[ Parent | on HN ]